Stock Chart

XTLB

$2.16 +1.41%
Score: 55.8 HOLD
Pro
Screener
Vol: 1.08x (vs SPY: 1.1x | vs QQQ: 1.1x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Falling Channel Bullish scenario quality 70/100
Measured-move target $2.5 (+15.8%)
Historically breaks up 64% of the time; target hit in 60% of up-breaks (n=559)
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and target are drawn on the chart below.
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About XTLB - XTL Biopharmaceuticals Ltd. American Depositary Shares

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). …

Key Statistics

Market Cap $5M

More XTLB Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This XTLB stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track XTLB's price movements with trendlines, gamma walls, and key support/resistance levels.